AKT1 and neoplasm: We demonstrate strong preliminary antitumor activity using sapanisertib in combination with metformin in a number of dose levels in molecularly selected patients of a range of tumor types: Disease control was observed in patients of various advanced malignancies harboring PTEN mutations and AKT/mTOR pathway alterations.